1. Home
  2. CSR vs CRVS Comparison

CSR vs CRVS Comparison

Compare CSR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo D/B/A Centerspace

CSR

D/B/A Centerspace

SELL

Current Price

$56.02

Market Cap

931.7M

Sector

Real Estate

ML Signal

SELL

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

SELL

Current Price

$10.18

Market Cap

843.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CSR
CRVS
Founded
1970
2014
Country
United States
United States
Employees
349
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
931.7M
843.7M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
CSR
CRVS
Price
$56.02
$10.18
Analyst Decision
Hold
Strong Buy
Analyst Count
9
6
Target Price
★ $63.57
$31.50
AVG Volume (30 Days)
177.9K
★ 876.3K
Earning Date
11-02-2026
11-05-2026
Dividend Yield
★ 5.44%
N/A
EPS Growth
N/A
★ 48.04
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$15.36
N/A
P/E Ratio
$62.27
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$52.00
$6.39
52 Week High
$69.61
$26.95

Technical Indicators

Market Signals
Indicator
CSR
CRVS
Relative Strength Index (RSI) 45.25 45.05
Support Level $54.25 $9.40
Resistance Level $57.61 $10.81
Average True Range (ATR) 1.44 0.72
MACD -0.26 0.07
Stochastic Oscillator 3.13 29.09

Price Performance

Historical Comparison
CSR
CRVS

About CSR D/B/A Centerspace

Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: